BACKGROUND: Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide and the fourth leading cause of cancer-related deaths. This article reviews the epidemiology, risk factors, pathogenesis, and prognosis of CRC with special emphasis on advances in the management of CRC over the past decade. METHODS: A review of the published English literature was conducted using the search engines PubMed, Medline, EMBASE, and Google Scholar. A total of 127 relevant publications were identified for further review. RESULTS: Most CRC are sporadic and are due to genetic instability and multiple somatic mutations. Approximately 80% of cancers are diagnosed at the early stage and are curable. The pathologic stage at presentation is the most important predictor of outcome after resection of early stage cancer. Surgery is the primary treatment modality for localized CRC. Advances in (neo)adjuvant chemotherapy and radiation have reduced the disease recurrence and increased survival in high risk diseases. Although recent advancements in combination chemotherapy and target agents have increased the survival of incurable CRC, it is remarkable that only selected patients with advanced CRC can be cured with multimodality therapy. CONCLUSION: Over the past decade, there has seen substantial progress in our understanding of and in the management of CRC.
BACKGROUND:Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide and the fourth leading cause of cancer-related deaths. This article reviews the epidemiology, risk factors, pathogenesis, and prognosis of CRC with special emphasis on advances in the management of CRC over the past decade. METHODS: A review of the published English literature was conducted using the search engines PubMed, Medline, EMBASE, and Google Scholar. A total of 127 relevant publications were identified for further review. RESULTS: Most CRC are sporadic and are due to genetic instability and multiple somatic mutations. Approximately 80% of cancers are diagnosed at the early stage and are curable. The pathologic stage at presentation is the most important predictor of outcome after resection of early stage cancer. Surgery is the primary treatment modality for localized CRC. Advances in (neo)adjuvant chemotherapy and radiation have reduced the disease recurrence and increased survival in high risk diseases. Although recent advancements in combination chemotherapy and target agents have increased the survival of incurable CRC, it is remarkable that only selected patients with advanced CRC can be cured with multimodality therapy. CONCLUSION: Over the past decade, there has seen substantial progress in our understanding of and in the management of CRC.
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Brenda Diergaarde; Alina Vrieling; Annemieke A van Kraats; Goos N P van Muijen; Frans J Kok; Ellen Kampman Journal: Carcinogenesis Date: 2003-03 Impact factor: 4.944
Authors: Heidi Nelson; Daniel J Sargent; H Sam Wieand; James Fleshman; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; David Ota Journal: N Engl J Med Date: 2004-05-13 Impact factor: 91.245
Authors: Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Robert Martin; Philip Paty; Yuman Fong; Andrew Grace; Alfred Cohen; Ronald DeMatteo; William Jarnagin; Leslie Blumgart Journal: J Am Coll Surg Date: 2003-08 Impact factor: 6.113
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Sabine Venderbosch; Johannes H de Wilt; Steven Teerenstra; Olaf J Loosveld; Aart van Bochove; Harm A Sinnige; Geert-Jan M Creemers; Margot E Tesselaar; Linda Mol; Cornelis J A Punt; Miriam Koopman Journal: Ann Surg Oncol Date: 2011-08-06 Impact factor: 5.344
Authors: Jie Chai; Jianbo Zhang; Dali Han; Wei Dong; Li Han; Lei Zou; Bin Feng; Baosheng Li; Wanli Ma Journal: Oncol Lett Date: 2020-05-21 Impact factor: 2.967
Authors: Ellen M Goldberg; Yaniv Berger; Divya Sood; Katherine C Kurnit; Josephine S Kim; Nita K Lee; S Diane Yamada; Kiran K Turaga; Oliver S Eng Journal: Ann Surg Oncol Date: 2021-05-06 Impact factor: 5.344
Authors: Sung Hwan Lee; Sung Hyun Kim; Jin Hong Lim; Sung Hoon Kim; Jin Gu Lee; Dae Joon Kim; Gi Hong Choi; Jin Sub Choi; Kyung Sik Kim Journal: Korean J Hepatobiliary Pancreat Surg Date: 2016-08-29
Authors: Hermann Brenner; Petra Schrotz-King; Bernd Holleczek; Alexander Katalinic; Michael Hoffmeister Journal: Dtsch Arztebl Int Date: 2016-02-19 Impact factor: 5.594